Pharmaceutical composition for use in the treatment of a neurodegenerative disease

2:

• The method according to claim 1, wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered parenterally.

3:

• The method according to claim 1, wherein the lixisenatide or pharmaceutically acceptable salt thereof is administered in a daily dose selected from the range of 10 μg to 20 μg.

4:

• The method according to claim 1, wherein the Parkinson's disease is associated with oxidative stress, inflammatory response, apoptosis and/or neuronal loss.

5:

• The method of claim 4, wherein the neuronal loss is a loss of dopaminergic neurons.

6:

• The method of claim 4, wherein the neuronal loss is a neuronal loss in the substantia nigra resulting in a lack of dopamine.

7:

• The method according to claim 1, wherein the Parkinson's disease is associated with cognitive impairment.

8:

• The method according to claim 1, wherein the Parkinson's disease is an early-stage Parkinson's disease.

9:

• The method according to claim 1, wherein the composition elicits a disease-modifying response.

10:

• The method according to claim 1, wherein the progression of the Parkinson's disease is slowed down.